These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9174681)

  • 1. MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography.
    Bergström M; Westerberg G; Németh G; Traut M; Gross G; Greger G; Müller-Peltzer H; Safer A; Eckernäs SA; Grahnér A; Långström B
    Eur J Clin Pharmacol; 1997; 52(2):121-8. PubMed ID: 9174681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron emission tomography quantification of [11C]-harmine binding to monoamine oxidase-A in the human brain.
    Ginovart N; Meyer JH; Boovariwala A; Hussey D; Rabiner EA; Houle S; Wilson AA
    J Cereb Blood Flow Metab; 2006 Mar; 26(3):330-44. PubMed ID: 16079787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an [11C]-harmine PET study.
    Sacher J; Houle S; Parkes J; Rusjan P; Sagrati S; Wilson AA; Meyer JH
    J Psychiatry Neurosci; 2011 Nov; 36(6):375-82. PubMed ID: 21463543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 11C-harmine as a tracer for monoamine oxidase A (MAO-A): in vitro and in vivo studies.
    Bergström M; Westerberg G; Långström B
    Nucl Med Biol; 1997 May; 24(4):287-93. PubMed ID: 9257326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors.
    Chiuccariello L; Cooke RG; Miler L; Levitan RD; Baker GB; Kish SJ; Kolla NJ; Rusjan PM; Houle S; Wilson AA; Meyer JH
    Int J Neuropsychopharmacol; 2015 Aug; 19(1):. PubMed ID: 26316187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites.
    Wiesel FA; Raaflaub J; Kettler R
    Eur J Clin Pharmacol; 1985; 28(1):89-95. PubMed ID: 3987791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.
    Bitsios P; Langley RW; Tavernor S; Pyykkö K; Scheinin M; Szabadi E; Bradshaw CM
    Br J Clin Pharmacol; 1998 Jun; 45(6):551-8. PubMed ID: 9663810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline.
    Gerardy J
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):793-802. PubMed ID: 7938567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
    Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A
    Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mode of action and characteristics of monoamine oxidase-A inhibition by moclobemide.
    Cesura AM; Kettler R; Imhof R; Da Prada M
    Psychopharmacology (Berl); 1992; 106 Suppl():S15-6. PubMed ID: 1546132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-lasting and reversible inhibition of monoamine oxidase-A by moclobemide.
    Da Prada M; Kettler R; Keller HH; Burkard WP
    Acta Psychiatr Scand Suppl; 1990; 360():103-5. PubMed ID: 2248059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.
    Koulu M; Scheinin M; Kaarttinen A; Kallio J; Pyykkö K; Vuorinen J; Zimmer RH
    Br J Clin Pharmacol; 1989 Feb; 27(2):243-55. PubMed ID: 2469451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
    Da Prada M; Kettler R; Keller HH; Burkard WP; Muggli-Maniglio D; Haefely WE
    J Pharmacol Exp Ther; 1989 Jan; 248(1):400-14. PubMed ID: 2783611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychometric performance in healthy subjects.
    Dingemanse J; Berlin I; Payan C; Thiede HM; Puech AJ
    Psychopharmacology (Berl); 1992; 106 Suppl():S68-70. PubMed ID: 1546145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moclobemide, an inhibitor of MAO-A, does not increase daytime plasma melatonin levels in normal humans.
    Scheinin M; Koulu M; Vakkuri O; Vuorinen J; Zimmer RH
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):73-82. PubMed ID: 2300680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations.
    Dingemanse J; Korn A; Pfefen JP; Güntert TW
    Psychopharmacology (Berl); 1992; 106 Suppl():S46-8. PubMed ID: 1347659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers.
    Van Haarst AD; Van Gerven JM; Cohen AF; De Smet M; Sterrett A; Birk KL; Fisher AL; De Puy ME; Goldberg MR; Musson DG
    Br J Clin Pharmacol; 1999 Aug; 48(2):190-6. PubMed ID: 10417495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats.
    Kettler R; Da Prada M; Burkard WP
    Acta Psychiatr Scand Suppl; 1990; 360():101-2. PubMed ID: 2248058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.
    Berlin I; Zimmer R; Thiede HM; Payan C; Hergueta T; Robin L; Puech AJ
    Br J Clin Pharmacol; 1990 Dec; 30(6):805-16. PubMed ID: 1705137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of monoamine oxidase inhibition on amphetamine-evoked changes in dopamine receptor availability in the living pig: a dual tracer PET study with [11C]harmine and [11C]raclopride.
    Jensen SB; Olsen AK; Pedersen K; Cumming P
    Synapse; 2006 Jun; 59(7):427-34. PubMed ID: 16485265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.